Polycystic ovary syndrome and risk of uterine leiomyomata

Fertility and Sterility

Volumn 87, Issue 5, 2007, Pages 1108-1115

  Wise, Lauren A ^a   Palmer, Julie R ^a   Stewart, Elizabeth A ^b   Rosenberg, Lynn ^a  

^a BOSTON UNIVERSITY   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

African Americans; females; leiomyoma; polycystic ovaries; premenopausal; Stein Leventhal syndrome; uterine neoplasms

Indexed keywords

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIAGNOSTIC TEST; DISEASE ASSOCIATION; ECHOGRAPHY; FEMALE; FOLLOW UP; HEALTH STATUS; HUMAN; HYSTERECTOMY; INCIDENCE; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; OUTCOME ASSESSMENT; OVARY POLYCYSTIC DISEASE; PAPANICOLAOU TEST; PHYSICIAN; PREMENOPAUSE; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUESTIONNAIRE; SELF REPORT; UNITED STATES; UTERUS MYOMA;

ADULT; AGED; COHORT STUDIES; FEMALE; HUMANS; LEIOMYOMA; MIDDLE AGED; POLYCYSTIC OVARY SYNDROME; PROSPECTIVE STUDIES; RISK FACTORS; UTERINE NEOPLASMS;

EID: 34247530369     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2006.11.012     Document Type: Article

References (47)

1. Guzick D. Polycystic ovary syndrome: symptomatology, pathophysiology, and epidemiology. Am J Obstet Gynecol 179 Suppl (1998) S89-S93
2. Guzick D.S. Polycystic ovary syndrome. Obstet Gynecol 103 (2004) 181-193
3. Zawadzki J.K., and Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A., Givens J.R., Haseltine F.P., Merriam G.R., et al. (Eds). Polycystic ovary syndrome (1992), Blackwell, Boston 377-384
4. The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 19 (2004) 41-47
5. Knochenhauer E.S., Key T.J., Kahsar-Miller M., Waggoner W., Boots L.R., and Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab 83 (1998) 3078-3082
6. Azziz R., Woods K.S., Reyna R., Key T.J., Knochenhauer E.S., and Yildiz B.O. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 89 (2004) 2745-2749
7. Rebuffe-Scrive M., Cullberg G., Lundberg P.A., Lindstedt G., and Bjorntorp P. Anthropometric variables and metabolism in polycystic ovarian disease. Horm Metab Res 21 (1989) 391-397
8. Dahlgren E., Friberg L.G., Johansson S., Lindstrom B., Oden A., Samsioe G., et al. Endometrial carcinoma; ovarian dysfunction-a risk factor in young women. Eur J Obstet Gynecol Reprod Biol 41 (1991) 143-150
9. Dahlgren E., and Janson P.O. Polycystic ovary syndrome: long-term effects. Ann Med 25 (1993) 307-308
10. Dahlgren E., Janson P.O., Johansson S., Lapidus L., and Oden A. Polycystic ovary syndrome and risk for myocardial infarction. Evaluated from a risk factor model based on a prospective population study of women. Acta Obstet Gynecol Scand 71 (1992) 599-604
11. Shemesh M. Actions of gonadotrophins on the uterus. Reproduction 121 (2001) 835-842
12. Baird D.D., Kesner J.S., and Dunson D.B. Luteinizing hormone in premenopausal women may stimulate uterine leiomyomata development. J Soc Gynecol Invest 13 (2006) 130-135
13. Tesarik J., Hazout A., and Mendoza C. Luteinizing hormone affects uterine receptivity independently of ovarian function. Reprod Biomed Online 7 (2003) 59-64
14. Stewart E.A. Gonadotropins and the uterus: is there a gonad-independent pathway?. J Soc Gynecol Invest 8 (2001) 319
15. Burroughs K.D., Howe S.R., Okubo Y., Fuchs-Young R., LeRoith D., and Walker C.L. Dysregulation of IGF-I signaling in uterine leiomyoma. J Endocrinol 172 (2002) 83-93
16. Giudice L.C., Irwin J.C., Dsupin B.A., Pannier E.M., Jin I.H., Vu T.H., et al. Insulin-like growth factor (IGF), IGF binding protein (IGFBP), and IGF receptor gene expression and IGFBP synthesis in human uterine leiomyomata. Hum Reprod 8 (1993) 1796-1806
17. Wolanska M., and Bankowski E. An accumulation of insulin-like growth factor I (IGF-I) in human myometrium and uterine leiomyomas in various stages of tumour growth. Eur Cytokine Netw 15 (2004) 359-363
18. Gloudemans T., Prinsen I., Van Unnik J.A., Lips C.J., Den Otter W., and Sussenbach J.S. Insulin-like growth factor gene expression in human smooth muscle tumors. Cancer Res 50 (1990) 6689-6695
19. Poretsky L., and Kalin M.F. The gonadotropic function of insulin. Endocr Rev 8 (1987) 132-141
20. Faerstein E., Szklo M., and Rosenshein N.B. Risk factors for uterine leiomyoma: a practice-based case-control study. II. Atherogenic risk factors and potential sources of uterine irritation. Am J Epidemiol 153 (2001) 11-19
21. Boynton-Jarrett R., Rich-Edwards J., Malspeis S., Missmer S.A., and Wright R. A prospective study of hypertension and risk of uterine leiomyomata. Am J Epidemiol 161 (2005) 628-638
22. Doi S.A.R., Al-Zaid M., Towers P.A., Scott C.J., and Al-Shoumer K.A.S. Irregular cycles and steroid hormones in polycystic ovary syndrome. Hum Reprod 20 (2005) 2402-2408
23. Rosenberg L., Adams-Campbell L.L., and Palmer J.R. The Black Women's Health Study: a follow-up study for causes and preventions of illness. J Am Med Wom Assoc 50 (1995) 56-58
24. Stewart E.A. Uterine fibroids. Lancet 357 (2001) 293-298
25. Wise L.A., Palmer J.R., Spiegelman D., Harlow B.L., Stewart E.A., Adams-Campbell L.L., et al. Influence of body size and body fat distribution on risk of uterine leiomyomata in U.S. black women. Epidemiology 16 (2005) 346-354
26. Ehrmann D.A. Polycystic ovary syndrome. N Engl J Med 352 (2005) 1223-1236
27. Loutradis D., Antsaklis A., Creatsas G., Hatzakis A., Kanakas N., Gougoulakis A., et al. The validity of gynecological ultrasonography. Gynecol Obstet Invest 29 (1990) 47-50
28. Dueholm M., Lundorf E., Hansen E.S., Ledertoug S., and Olesen F. Accuracy of magnetic resonance imaging and transvaginal ultrasonography in the diagnosis, mapping, and measurement of uterine myomas. Am J Obstet Gynecol 186 (2002) 409-415
29. Schwartz S.M., and Marshall L.M. Uterine leiomyomata. In: Goldman M.B., and Hatch M.C. (Eds). Women and health (2000), Academic Press, San Diego, CA 240-252
30. Robboy S.J., Andersen M.C., and Russell P. Pathology of the female reproductive tract (2002), Churchill Livingstone, London
31. Wise L.A., Palmer J.R., Stewart E.A., and Rosenberg L. Age-specific incidence rates for self-reported uterine leiomyomata in the Black Women's Health Study. Obstet Gynecol 105 (2005) 563-568
32. SAS Institute, Inc. SAS/STAT user's guide, version 8.02 (2002), SAS Institute, Cary, NC
33. Greenland S. Modeling and variable selection in epidemiologic analysis. Am J Public Health 79 (1989) 340-349
34. Taylor A.E., McCourt B., Martin K.A., Anderson E.J., Adams J.M., Schoenfeld D., et al. Determinants of abnormal gonadotropin secretion in clinically defined women with polycystic ovary syndrome. J Clin Endocrinol Metab 82 (1997) 2248-2256
35. Pasquali R., Casimirri F., Venturoli S., Antonio M., Morselli L., Reho S., et al. Body fat distribution has weight-independent effects on clinical, hormonal, and metabolic features of women with polycystic ovary syndrome. Metabolism 43 (1994) 706-713
36. Elting M.W., Korsen T.J., Rekers-Mombarg L.T., and Schoemaker J. Women with polycystic ovary syndrome gain regular menstrual cycles when ageing. Hum Reprod 15 (2000) 24-28
37. Bili H., Laven J., Imani B., Eijkemans M.J., and Fauser B.C. Age-related differences in features associated with polycystic ovary syndrome in normogonadotrophic oligo-amenorrhoeic infertile women of reproductive years. Eur J Endocrinol 145 (2001) 749-755
38. Berker B., Emral R., Demirel C., Corapcioglu D., Unlu C., and Kose K. Increased insulin-like growth factor-I levels in women with polycystic ovary syndrome, and beneficial effects of metformin therapy. Gynecol Endocrinol 19 (2004) 125-133
39. Wise L.A., Palmer J.R., Harlow B.L., Spiegelman D., Stewart E.A., Adams-Campbell L.L., et al. Reproductive factors, hormonal contraception and risk of uterine leiomyomata in African-American women: a prospective study. Am J Epidemiol 159 (2004) 113-123
40. Gadducci A., Gargini A., Palla E., Fanucchi A., and Genazzani A.R. Polycystic ovary syndrome and gynecological cancers: is there a link?. Gynecol Endocrinol 20 (2005) 200-208
41. Fauser B.C., Pache T.D., Lamberts S.W., Hop W.C., de Jong F.H., and Dahl K.D. Serum bioactive and immunoreactive luteinizing hormone and follicle-stimulating hormone levels in women with cycle abnormalities, with or without polycystic ovarian disease. J Clin Endocrinol Metab 73 (1991) 811-817
42. van Santbrink E.J., Hop W.C., and Fauser B.C. Classification of normogonadotropic infertility: polycystic ovaries diagnosed by ultrasound versus endocrine characteristics of polycystic ovary syndrome. Fertil Steril 67 (1997) 452-458
43. Laven J.S., Imani B., Eijkemans M.J., and Fauser B.C. New approach to polycystic ovary syndrome and other forms of anovulatory infertility. Obstet Gynecol Surv 57 (2002) 755-767
44. Nakamura Y., Yoshimura Y., Yamada H., Ubukata Y., Ando M., and Suzuki M. Treatment of uterine leiomyomata with a luteinizing hormone-releasing hormone agonist: the possibility of nonsurgical management in selected perimenopausal women. Fertil Steril 55 (1991) 900-905
45. Stewart E.A., and Friedman A.J. Steroidal treatment of myomas: preoperative and long-term medical therapy. Semin Reprod Endocrinol 10 (1992) 344-357
46. Abma J.C., Chandra A., Mosher W.D., Peterson L.S., and Piccinino L.J. Fertility, family planning, and women's health: new data from the 1995 National Survey of Family Growth. [Series 23, No. 9]. Vital Health Stat 23 (1997) 19
47. Flegal K.M., Carroll M.D., Ogden C.L., and Johnson C.L. Prevalence and trends in obesity among US adults, 1999-2000. J Am Med Assoc 288 (2002) 1723-1727